PET imaging of solid tumors with 89Zr-DFO-starPEG
Part of Cancer clinical trials.
This early-phase trial tests a new imaging agent called 89Zr-DFO-starPEG that may help doctors see solid tumors more clearly on PET scans. It is a safety and imaging study, not a treatment, and may help find tumors in people with various types of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a solid tumor cancer that has been confirmed by a biopsy or lab test.
- You must have at least one tumor that is 1 cm or larger on a CT, MRI, or PET scan, or a spot on your bones that shows up on a PET scan.
- You must be able to have a PET/CT scan and have good liver and kidney function (based on blood tests in the last 4 weeks).
- If you are able to become pregnant, you must agree to use two forms of birth control or abstain from sex for 1 month after the study drug is given.
- You cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new imaging tracer called [89Zr]DFO-YS5 that may help detect certain cancers on a PET-CT scan. The goal is to see if this tracer is safe and works well for finding tumors, which could one day help doctors plan better treatments.
This study uses a special PET scan to see if a new imaging agent can help find and monitor certain solid tumors. It is for people with colon, rectal, sarcoma, breast, lung, head and neck, esophageal, stomach, pancreas, bladder cancers, or glioblastoma who have had standard treatment before surgery.
This trial uses a special PET scan to take pictures of certain solid tumors. The scan uses a new dye that may help doctors see the tumors more clearly. You may be eligible if you have one of the listed cancers and are between 18 and 75 years old with good daily function.
This study tests a new imaging agent that helps PET scans show cancer more clearly. It may help doctors see where cancer is in your body and plan your treatment better.
This trial tests a special imaging agent (a nanobody probe) that targets a protein called CD147 on tumor cells. If you have a solid tumor like melanoma, liver, colorectal, pancreatic, breast, stomach, or lung cancer, the PET scan may help doctors see your cancer more clearly.
This trial tests a new imaging agent that may help doctors see tumors more clearly during a PET scan. It is for people with certain types of cancer who are willing to have a biopsy of their tumor.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.